CME / ABIM MOC

Recognizing and Referring Patients With Retinal Vein Occlusion

Authors: Victor Cisneros, MD, MPH, CPH; Charles Vega, MD; Dorothy Hitchmoth, OD; Steven M. Silverstein, MD, FACS; David Brown, MD
CME / ABIM MOC Released: 11/8/2023
Valid for credit through: 11/8/2024, 11:59 PM EST

Credits Available

Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.75 ABIM MOC points

Optometry - This course is COPE approved for 0.75 hours of CE credit.

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for general ophthalmologists, retinal specialists, optometrists, emergency medicine physicians, and primary care physicians.

The goal of this activity is for learners to be better able to make appropriate clinical decisions across multiple touchpoints in the retinal vein occlusion (RVO) patient journey.

At the conclusion of this program, learners will be better able to:

Recognize clinical signs of RVO
Diagnose RVO
Manage patients with RVO (via referral or direct treatment)

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Victor Cisneros, MD, MPH, CPH

Faculty, Emergency Medicine Department
Eisenhower Medical Center
Director of Diversity, Equity & Inclusion
Graduate Medical Education
Eisenhower Health
Rancho Mirage, California

Disclosures

Victor Cisneros, MD, MPH, CPH, has no relevant financial relationships.

Charles Vega, MD

Clinical Professor, Family Medicine
Assistant Dean
School of Medicine
University of California, Irvine

Disclosures

Charles Vega, MD, has the following relevant financial relationships:
Consultant or advisor for: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Dorothy Hitchmoth, OD

Professor of Optometry and Internal Medicine
Optometrist and Owner
Dr Dorothy L. Hitchmoth, PLLC
Vice President of Clinical Affairs
Percept Corporation
New London, New Hampshire

Disclosures

Dorothy Hitchmoth, OD, has the following relevant financial relationships:
Consultant or advisor for: Allergan; Carl Zeiss Meditec; EyePromise; Google Health; RVL Pharmaceuticals, Inc; Sun Pharmaceutical Industries, Ltd.; Twenty/Twenty Therapeutics; Versant Health
Owns stock (privately owned) in: Percept Corporation

Steven M. Silverstein, MD, FACS

Clinical Professor of Ophthalmology
Kansas City University of Medicine and Biomedical Sciences
President, Silverstein Eye Centers
Kansas City, Missouri

Disclosures

Steven M. Silverstein MD, FACS, has no relevant financial relationships.

David Brown, MD

Clinical Professor of Ophthalmology
Baylor College of Medicine
Retina Consultants of Texas
Houston, Texas

Disclosures

David Brown, MD, has the following relevant financial relationships:
Consultant or advisor for: 4DMT; Adverum Biotechnologies, Inc.; AGTC; Alexion Pharmaceuticals, Inc.; Annexon, Inc.; Apellis Pharmaceuticals; Bayer HealthCare; Biogen; Boehringer Ingelheim Pharmaceuticals, Inc.; Celltrion Healthcare; Chengdu Kanghong Pharmaceutical Group Co., Ltd.; Clearside Biomedical, Inc.; Coherus BioSciences, Inc.; Gemini Therapeutics, Inc.; Glaukos Corporation; Heidelberg Engineering; IVERIC Bio, Inc.; Kodiak Sciences; Lineage Cell Therapeutics, Inc.; Molecular Partners A.G.; Novartis AG; Ocular Therapeutix, Inc.; Ocuphire Pharma, Inc.; Optos; Pontifax; PPD, Inc.; Ray Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc.; RetinAI Medical AG; Samsung Bioepis Co., Ltd.; Senju Pharmaceutical Co., Ltd.; SciNeuro Therapeutics, Inc.; Smilebiotek Zhuhai Limited; Stealth BioTherapeutics Inc.; Verseon Corporation
Research funding from: Adverum Biotechnologies, Inc.; Aldeyra Therapeutics, Inc.; Alexion Pharmaceuticals, Inc.; Alkahest, Inc.; Alimera Sciences; Amgen Inc.; Annexon, Inc.; Apellis Pharmaceuticals; Aura Biosciences, Inc.; Bayer HealthCare; Boston Image Reading Center; Boehringer Ingelheim Pharmaceuticals, Inc.; Clearside Biomedical, Inc.; EyePoint Pharmaceuticals, Inc.; Gemini Therapeutics, Inc.; Genentech, Inc./Roche; Graybug Vision, Inc.; Gyroscope Therapeutics; Ionis Pharmaceuticals; iRenix Medical, Inc.; IVERIC Bio, Inc.; Kodiak Sciences; LumiThera, Inc.; Nanoscope Therapeutics, Inc.; Neurotech Pharmaceuticals; NGM Biopharmaceuticals; Novartis AG; Ocular Therapeutix, Inc.; Ocuphire Pharma, Inc.; OIRRC; ONS; Opthea Limited; Ophthotech Corporation; Optos; Oxurion; Oyster Point Pharma, Inc.; Regeneron Pharmaceuticals, Inc.; REGENXBIO Inc.; Roche; Samchundang Pharm Co., Ltd.; Samsung; Sandoz; Santen Pharmaceutical Co., Ltd.; Senju Pharmaceutical Co., Ltd.; Stealth BioTherapeutics Inc.; Unity; Xbrane Biopharma; Zeiss
Contracted researcher for: Adverum Biotechnologies, Inc.; Aldeyra Therapeutics, Inc.; Alexion Pharmaceuticals, Inc.; Alkahest, Inc.; Alimera Sciences; Amgen Inc.; Annexon, Inc.; Apellis Pharmaceuticals; Aura Biosciences, Inc.; Bayer HealthCare; Boston Image Reading Center; Boehringer Ingelheim Pharmaceuticals, Inc.; Carl Zeiss Meditec; Clearside Biomedical, Inc.; EyePoint Pharmaceuticals, Inc.; Gemini Therapeutics, Inc.; Genentech, Inc./Roche; Graybug Vision, Inc.; Gyroscope Therapeutics; Ionis Pharmaceuticals; iRenix Medical, Inc.; IVERIC Bio, Inc.; Kodiak Sciences; LumiThera, Inc.; Nanoscope Therapeutics, Inc.; Neurotech Pharmaceuticals; NGM Biopharmaceuticals; Novartis AG; Ocular Therapeutix, Inc.; Ocuphire Pharma, Inc.; OIRRC; ONS; Opthea Limited; Ophthotech Corporation; Optos; Oxurion; Oyster Point Pharma, Inc.; Regeneron Pharmaceuticals, Inc.; REGENXBIO Inc.; Roche; Samchundang Pharm Co., Ltd.; Samsung; Sandoz; Santen Pharmaceutical Co., Ltd.; Senju Pharmaceutical Co., Ltd.; Stealth BioTherapeutics Inc.; Unity; Xbrane Biopharma
Patent beneficiary of: Optos, Camera Software used to dewarp images
Stock options from: Adverum Biotechnologies, Inc.; Clearside Biomedical, Inc.

Editors

Pakinam Aboulsaoud, PharmD

Senior Medical Education Director, Medscape, LLC

Disclosures

Pakinam Aboulsaoud, PharmD, has no relevant financial relationships.

Chii Shyang Fong, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Chii Shyang Fong, PhD, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

Developed through a partnership between the Postgraduate Institute for Medicine and Medscape.

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Optometrists

In support of improving patient care, Postgraduate Institute for Medicine (PIM) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation: Postgraduate Institute for Medicine is accredited by COPE to provide continuing education to optometrists.

Credit Statement: This course is COPE approved for 0.75 hours of CE credit. Activity # 126281 and Course ID 85046-TD. Check with your local state licensing board to see if this counts toward your CE requirement for re-licensure.

Contact this provider: www.pimed.com

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

Optometrists

In order to obtain your CME/CE certificate, please follow the steps below at the conclusion of the activity:

Go to www.cmeuniversity.com
Login or Create a New Account (will take less than 1 minute).
a. If you receive a message when creating a new account that “the email you entered is already in use”, please click the Forgot my Username or Password link to have your Username and Password sent to you via email.

b. After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page.
Type in 17947 at the top of the page, “Find Post-Test/Evaluation by Course”, and click enter.
Click on the activity title when it appears.
Choose the type of credit you desire.
Complete the online assessment.
Receive an immediate CME/CE Certificate to download and/or print for your files.

If you have questions regarding the certification of this activity, please contact PIM via email at [email protected]

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose.

From Medscape Education Emergency Medicine

CME / ABIM MOC

Recognizing and Referring Patients With Retinal Vein Occlusion

Authors: Victor Cisneros, MD, MPH, CPH; Charles Vega, MD; Dorothy Hitchmoth, OD; Steven M. Silverstein, MD, FACS; David Brown, MDFaculty and Disclosures

CME / ABIM MOC Released: 11/8/2023

Valid for credit through: 11/8/2024, 11:59 PM EST

processing....

Contents of This CME Activity

Primary & Emergency Care Clinician Handout

Specialty Eye Care Clinician Handout

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Recognizing and Referring Patients With Retinal Vein Occlusion

Dr Cisneros highlights the goal and overview of the program.
Victor Cisneros, MD, MPH, CPH

Retinal Vein Occlusion: The Emergency Medicine Physician Perspective

Dr Cisneros highlights the diagnostic challenges of retinal vein occlusion in the emergency department.
Victor Cisneros, MD, MPH, CPH

Retinal Vein Occlusion: The Primary Care Physician Perspective

Dr Vega emphasizes the need for promptly referring patients with RVO in the primary care setting.
Charles Vega, MD

Retinal Vein Occlusion: The Optometrist Perspective

Dr Hitchmoth presents diagnostic strategies for RVO in optometry.
Dorothy Hitchmoth, OD

Retinal Vein Occlusion: The General Ophthalmology Perspective

Dr Silverstein explains the approaches ophthalmologists take in treating RVO.
Steven M. Silverstein MD, FACS

The Treatment Landscape of Retinal Vein Occlusion

Dr Brown, a retina specialist, discusses the latest therapy options for retinal vein occlusion.
David Brown, MD

Educational Impact Challenge

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

Page 1 of 9

CME / ABIM MOC Information Download Slides

Activity Transcript

PDF Downloads

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Victor Cisneros, MD, MPH, CPH

Charles Vega, MD

Dorothy Hitchmoth, OD

Steven M. Silverstein, MD, FACS

David Brown, MD

Editors

Pakinam Aboulsaoud, PharmD

Chii Shyang Fong, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

CME / ABIM MOC

Recognizing and Referring Patients With Retinal Vein Occlusion

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Victor Cisneros, MD, MPH, CPH

Charles Vega, MD

Dorothy Hitchmoth, OD

Steven M. Silverstein, MD, FACS

David Brown, MD

Editors

Pakinam Aboulsaoud, PharmD

Chii Shyang Fong, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

Accreditation Statements

For Optometrists

For Physicians

Instructions for Participation and Credit

Optometrists

Recognizing and Referring Patients With Retinal Vein Occlusion

Contents of This CME Activity

Primary & Emergency Care Clinician Handout Specialty Eye Care Clinician Handout

Recognizing and Referring Patients With Retinal Vein Occlusion

Retinal Vein Occlusion: The Emergency Medicine Physician Perspective

Retinal Vein Occlusion: The Primary Care Physician Perspective

Retinal Vein Occlusion: The Optometrist Perspective

Retinal Vein Occlusion: The General Ophthalmology Perspective

The Treatment Landscape of Retinal Vein Occlusion

Educational Impact Challenge

PDF Downloads

Primary & Emergency Care Clinician Handout

Specialty Eye Care Clinician Handout